The Rivaroxaban Once Daily oral Direct factor Xa inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation study (ROCKET-AF) was a randomized, double-blind, double-dummy, event-driven trial, which aimed to establish the non-inferiority of rivaroxaban compared with warfarin in patients with non-valvular AF who have a history of stroke or at least 2 additional independent risk factors for future stroke. The gene discussed is F10; the disease is stroke disorder.